Effect of Vitamins D3 and K2 in uOc and Insulin Serum Levels in Patients With Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-14

Study Completion Date

2019-02-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction: Patients with DM2 have chronic hyperglycemia derived from a decrease in insulin sensitivity, cause of comorbidities such as bone demineralization, decreasing quality of life and increasing mortality. This could be related to changes in the serum levels of carboxylated Osteocalcin and Insulin, together with the deficit the daily consumption of vitamins D3 and K, which is crucial for the process of mineralization of the bone matrix.

Research question: What is the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus?

Hypothesis: Supplementation with Vitamins D3 and K2 modifies the serum levels of Carboxylated Osteocalcin and Insulin in patients with Type 2 Diabetes mellitus.

General Objectives: To assess the effect of supplementation with Vitamins D3 and K2 on serum levels of Carboxylated and Non-Carboxylated Osteocalcin in patients with Type 2 Diabetes mellitus.

Material and Methods: Clinical trial, double blind, randomization, 40 patients with DM2, 35-65 years, supplementation (3 months), clinical and laboratory determinations (uOC and Insulin).

* Group 1: Vitamin D3 1000UI + Placebo
* Group 2: Vitamin K2 100 mcg + Placebo
* Group 3 (Positive Control): Vitamins D3 1000UI + K2 100 mcg

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)

NCT02366481

Obesity Insulin Resistance Insulin Sensitivity +2 more

UNKNOWN NA

Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification

NCT01922804

Metabolic Bone Disorder

UNKNOWN NA

Effect of Vitamin D Supplementation on Hemoglobin A1c

NCT01354262

Diabetes Mellitus Vitamin D Deficiency

COMPLETED PHASE2

Relation Between Plasma Vitamin K2 and Glycemic Control and Metabolic Parameters in Type 2 Diabetic Patients.

NCT04387019

Vitamin k2 in Type 2 DM

COMPLETED

Efect Supplementation Vitamin D in Diabetes Mellitus Type 2

NCT07019415

Diabetes Mellitus Type 2 (T2DM)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 diabetes mellitus is a group of metabolic disorders characterized by chronic hyperglycemia, being one of the main causes of mortality in our country.

There are different comorbidities, including bone demineralization, which involve an imbalance in the process of bone formation and resorption, which entails the risk of decreasing bone mineral density. These processes could be related to the serum levels of Non-carboxylated Osteocalcin and Insulin, said molecule locally modulates the process of bone mineralization.

On the other hand, it is known that the daily consumption of vitamins in a general diet in our population (specifically including vitamins D3 and K), is below the necessary basic requirements, so considering crucial elements for the benefit of Bone matrix mineralization, which is why the present study proposes supplementation with the aforementioned vitamins in patients with Type 2 DM, to avoid a decrease in bone mineral density, increasing the mortality rate of individuals suffering from it.

1. \- The study subjects from the West of the country were invited to participate in the research protocol, where their objective was explained and the signing of the consent was requested under information, where a structured evaluation was subsequently carried out consisting of :

a) Comprehensive clinical evaluation (including general sociodemographic data of a complete medical history).
2. \- Once the previous data was obtained, the randomization of the treatment was carried out, classifying the patients in the following groups:

* Group 1 Vitamin D3 1000UI + Placebo (Calcined Magnesia).
* Group 2 Vitamin K2 100 mcg + Placebo (Calcined Magnesia).
* Group 3 (Positive Control) Vitamins D3 1000UI + K2 100 mcg.
3. \- Blood sample collection through Punzocat, which was placed in a red tube, for subsequent centrifugation at 3500rpm x 15 minutes, performing aliquots of the serum obtained and stored at -80 ° C and thus perform the pertinent quantifications of the molecules to study.
4. \- Quantification of serum levels of non-carboxylated Osteocalcin and Insulin

a) The determinations corresponding to the serum levels of Non-carboxylated Osteocalcin and Insulin were made, both baseline prior to the intervention as well as the final quantification, once the supplementation was finished, by means of the indirect ELISA technique (commercial reagents -Takara were used - for the realization of these determinations), which involved the following process: In a plate the wells were coated with a first antibody, then a wash was performed to remove the excess antibody, after that, the sample in which the antigen was found was added, which was retained in the well after being recognized by the first antibody, a second wash was subsequently made to remove unbound material, then a solution with a second labeled anti-antigen antibody was applied. Thus each antigen molecule was bound to an antibody in the base that kept it fixed and a second antibody for its reaction and labeling. Finally, the plate was introduced into a spectophotometer and the absorbance was measured at a length of 450 nm, for both non-carboxylated Osteocalcin and Insulin.
5. \- The quantification in serum of cholesterol and triglycerides was carried out by using the fully automated random access analyzer equipment for clinical chemistry, model ERBA XL 200.
6. \- The evaluation of the HOMA index was calculated by using the equations HOMA-IR and HOMA-B, for insulin resistance (IR) and Percentage, respectively.
7. \- The daily of adherence to treatment was provided, so that they recorded all those important events that would ensure adequate intake of vitamins, as well as adverse reactions to them, which were evaluated in scheduled appointments, in addition to each The corresponding bottles were delivered consecutively for each of the 3 months of intervention, with the corresponding vitamins for each patient according to their allocation group.
8. \- Finally, in the last visit the results obtained during the whole study were made known to each of the patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Bone Loss Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Controlled clinical trial, with randomization simple, double blind.

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

randomization simple, double blind.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Vitamin D3 1000UI + Placebo (Calcined Magnesia).

Group Type EXPERIMENTAL

Supplementation with Vitamin D3 y K2

Intervention Type DIETARY_SUPPLEMENT

Supplementation at a dose of 1 capsule every 24 hours x 3 months

Group 2

Vitamin K2 100 mcg + Placebo (Calcined Magnesia).

Group Type EXPERIMENTAL

Supplementation with Vitamin D3 y K2

Intervention Type DIETARY_SUPPLEMENT

Supplementation at a dose of 1 capsule every 24 hours x 3 months

Group 3

Vitamin D3 1000UI + Vitamin K2 100 mcg

Group Type ACTIVE_COMPARATOR

Supplementation with Vitamin D3 y K2

Intervention Type DIETARY_SUPPLEMENT

Supplementation at a dose of 1 capsule every 24 hours x 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Supplementation with Vitamin D3 y K2

Supplementation at a dose of 1 capsule every 24 hours x 3 months

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Originating and residents of Western Mexico
* Both genres
* Age of 30-75 years
* Diagnosis of DM2 (ADA Criteria) of at least 5 years of evolution
* Sign an informed consent letter.

Exclusion Criteria

* Use of active drugs for bone mineralization
* Pregnancy
* Lactation
* Creatinine or transaminase more than double the upper limit
* Diet added with calcium or vitamins (D, K).

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No